# Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2025

- Company: [Can-Fite BioPharma Ltd.](/companies/canf.md) (CIK 1536196)
- Form: 20-F
- Filed: 2026-03-26
- Accepted by EDGAR: Mar 26, 2026, 10:05 ET
- Period: 2025-12-31
- Accession: 0001213900-26-034447
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/ea0282586-20f_canfite.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2025-01-01 to 2025-12-31 | $405.0k | us-gaap:Revenues |
| Research and development | 12 months, 2025-01-01 to 2025-12-31 | $6.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2025-01-01 to 2025-12-31 | −$9.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2025-01-01 to 2025-12-31 | $284.0k | us-gaap:InterestExpenseNonoperating |
| Net income | 12 months, 2025-01-01 to 2025-12-31 | −$9.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2025-01-01 to 2025-12-31 | −$5.97 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2025-01-01 to 2025-12-31 | −$5.97 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2025-01-01 to 2025-12-31 | 1,646,208 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | −$8.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2025-01-01 to 2025-12-31 | $2.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2025-12-31 | $5.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-12-31 | $9.4m | us-gaap:AssetsCurrent |
| Total assets | at 2025-12-31 | $9.5m | us-gaap:Assets |
| Current liabilities | at 2025-12-31 | $2.7m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2025-12-31 | $5.6m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2025-12-31 | 2,618,425 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1536196/000121390026034447/ea0282586-20f_canfite.htm

Filed Mar 26, 2026.
Source: SEC EDGAR, the filing index for accession 0001213900-26-034447. Last ingested by Listed: Nov 9, 2026, 17:23 ET. No prices; not investment advice.